Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Regeneron Pharmaceuticals and Sanofi are conducting a clinical study titled A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis. The study aims to evaluate the pharmacokinetics and safety of Dupilumab in young participants suffering from Prurigo Nodularis, a chronic skin condition. This research is significant as it could lead to new treatment options for a demographic that currently has limited therapeutic choices.
The intervention being tested is Dupilumab, an experimental drug administered subcutaneously. It is designed to treat Prurigo Nodularis by targeting specific pathways involved in the inflammatory response, potentially providing relief from symptoms.
This Phase 3 study is interventional with a single-group assignment. It is open-label, meaning there is no masking, and its primary purpose is treatment. Participants will undergo a 42 to 44-week process, including screening, treatment, and follow-up periods.
The study began on May 15, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on August 19, 2025. These timelines are crucial for investors tracking the progress and potential market entry of Dupilumab for this indication.
The ongoing study could significantly impact the stock performance of Regeneron and Sanofi, as successful results may enhance their market position and investor confidence. The development of Dupilumab for Prurigo Nodularis could also influence the competitive landscape, potentially affecting other companies in the dermatological treatment sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.